drugset
drugset / Trial / NCT04414852

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

NCT04414852 ↗

Phase 1 Unknown 24 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.

Timeline

Start
2020-06-05
Primary completion
2021-01-15
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 250 mg —

Indications

No indication recorded.